Role of oxidative stress in antituberculous drugs (individuals and combined) cytotoxicity in HepG2 cells by Elmorsy, Ekramy et al.
* To whom correspondence should be addressed.
Malays. Appl. Biol. (2016) 45(2): 151–158
ROLE OF OXIDATIVE STRESS IN ANTITUBERCULOUS DRUGS
(INDIVIDUALS AND COMBINED) CYTOTOXICITY
IN HEPG2 CELLS
EKRAMY ELMORSY1, SOHAYLA M. ATTALLA1*, AYAT AL-GHAFARI2
and LUCKY LEGBOSI NWIDU3
1Department of Forensic Medicine and Clinical Toxicology, Faculty of Medicine,
Mansoura University, Egypt and International Medical School,
Management & Science University Malaysia
2Department of Biochemistry, Faculty of Science, King Abdulaziz University (KAU),
Jeddah, Kingdom of Saudi Arabia
3Department of Pharmacology and Toxicology, Faculty of Pharmacy, Niger Delta University,
Wilberforce Island, P.M.B. 071Yenegoa, Bayelsa State, Nigeria
*Email: dr_sohayla@hotmail.com
Accepted 26 October 2016, Published online 21 December 2016
ABSTRACT
Hepatotoxicity is a common side and toxic effect of Antituberculous (Anti-TB) drugs with reported higher incidence with
anti-TB combinations. Oxidative stress was shown to have a role. This study examined oxidative stress effects of the first
line Anti-TB drugs; Rifampicin (RIF), isoniazid (INH) and pyrazinamide PZA (individually and combined) on HepG2 cells.
MTT assay (3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) was used to study the cytotoxic effect of the
tested Anti-TB drugs. The effect of anti-TB drugs on total glutathione HepG2 cells and the production of reactive oxygen
species (ROSs) were studied (individually and in combinations). Furthermore, the protective effect of the antioxidant reduced
glutathione was assayed.  The data revealed that the tested anti-TB were cytotoxic to HepG2 cells. RIF was the most potent.
The tested drugs in their estimated IC50s, to different extents, enhanced significantly (P<0.0001) ROSs production and decreased
total glutathione (P <0.0001). Furthermore, 48 hours pre-treatment with INH (3mM) significantly increased ROS production
and decreased glutathione with RIF (0.1mM) (P <0.01 and P <0.05 respectively) and PZA (10 mM) (P <0.01 and P <0.05
respectively). Combined RIF (0.1mM) and INH (3mM) significantly decreased total glutathione (P<0.05 for each) and
increased ROSs production (P<0.05) in HepG2 cells (P<0.05 for each). Interestingly, reduced glutathione (GSH) significantly
decreased the cytotoxicity of RIF and INH (P=0.005 and 0.015, respectively). These data showed that oxidative stress play a
crucial role in anti-TB induced hepatotoxicity, which can be alleviated by inclusion of antioxidant in therapy, though there is
need of clinical trials. Moreover, combined anti-TB therapy should be considered as a risk factor with any other oxidative
liver injuries.
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INTRODUCTION
Tuberculosis (TB) is one of the most serious
infectious diseases affecting approximately one
third of the world population specially in
developing world (Brewer & Heymann, 2004). In
2012, there were an estimated 8.6 million incident
cases of TB and 1.3 million people died from the
disease (WHO report, 2013). Recently, anti-TB drugs
are available with high cure rates. However, their
hepatotoxic effect is the major problem suffered by
patients going under the scheduled prolonged
therapeutic courses of the anti-TB drugs. Generally,
the incidence of anti-TB drugs induced hepato-
toxicity was estimated to be 5%-28% of patients
treated with anti-TB drugs (Ostapowicz et al., 2002;
Navarro & Senior, 2006). Shakya et al (2006)
reported that anti-TB induced hepatotoxicity can
cause different forms of pathological liver insults
which may lead to permanent injury and death, if
not predicted in the early stages.
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Drugs induced hepatotoxicities were reported
in patients receiving the first line anti-TB drugs;
Isoniazid (INH), Rifampicin (RIF) and Pyrazinamide
(PZA) (Singla et al., 2010). INH was reported to be
the main offending agent for the occurrence of anti-
TB- drugs hepatotoxicity (Singh et al., 2011). A lot
of risk factors were suggested for anti-TB drugs
induced hepatotoxicity mainly young aged
populations (Shakya et al., 2006), female gender
(Makhlouf et al., 2008) and malnutrition (Mahmood
et al., 2007). Oxidative stress mediates the onset
and propagation of many pathological insults and
drug induced toxicities (Pereira et al., 2012).
Investigating the potential mechanism of oxidative
stress in hepatotoxicity would require in-depth
understanding of how ROS are generated,
disruptions that occur in oxidant homeostasis,
mitochondrial dysfunction and how clinically
approved drugs induced side effects (Ott et al.,
2007; Daevall et al., 2012). This knowledge is
critical in preventing drugs induced liver injury
(DILI) or hepatotoxicity.
Anti-TB drugs induced oxidative stress was
suggested to play a crucial role in their induced
hepatotoxicity (Attri et al., 2000; Funde et al.,
2013). However, the oxidative effect of each
individual agent is difficult to be evaluated in
patients, as they must undergo the combination
therapeutic courses containing more than single
anti-TB agents. Rifampicin is also reported to
infrequently cause hepatocellular injury and
potentiate hepatotoxicities of other anti-TB
medications (Menzies et al., 2004). Other studies
incriminate rifampicin to activate hepatocyte
pregnane X receptors, leading to induction of
cytochromes and induction of uridine diphosphate-
glucuronosyl-transferases and P-glycoprotein
transport implicated in the metabolism of other
drugs (Burk et al., 2004; Rae et al., 2001).
Rifampicin interacts with numerous drugs
metabolized by these and other hepatic enzymes
(Niem et al., 2003). Therefore, prescribing
combination of these three Anti-Tb drugs in the
management of tuberculosis might interfere with
other metabolic pathways to promote observed
upregulation of ROSs and downregulation of total
glutathione to exacerbate oxidative stress and drug
induced hepatotoxicity. INH metabolite, mono-
acetyl hydrazine produced by acetylation and
dehydrazination (Timmins & Deretic, 2006), was
reported to be responsible for its hepatotoxic
effects through interaction with cytochrome P450
system, modulating increased oxidative stress and
altering mitochondrial permeability alterations by
peroxidation of their membranes lipid contents
(Sardao et al., 2008; Chowdhury et al., 2006).
Pyrazinamide alters nicotinamide acetyl dehydro-
genase levels in rat liver (Shibata et al., 2001),
which might result in generation of free radical
species inducing oxidative stress.
There may be shared mechanisms of injury for
isoniazid and pyrazinamide, due to molecular
structural activity relationship (SAR). Therefore, the
justification for the present work is to enhance better
prediction of mechanisms of the role of oxidative
stress in anti-TB drugs induced cytotoxic effect on
Hep G2 cells via highlight the biochemical
alterations, namely quantification of reduced
glutathione (GSH) and increased reactive oxygen
species (ROSs) production levels underlying the
tested drugs induced cytotoxic effect on HepG2
cells. The effect of the drugs was assayed
individually and in combinations to simulate their
clinical therapeutic courses. In addition, protective




Chemicals and media components, used in this
study, were purchased from Sigma Chemicals, USA
unless other source is mentioned.
Cell culture
Human hepatocellular carcinoma cells (HepG2
cells) were grown in serum-free PC-1 medium
(Cambrex, Verviers, Belgium) supplemented with
2 mM L-glutamine. Cells were incubated at 37ºC in
a humidified atmosphere with 5% CO2.
MTT (3-(4,5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide) assay
The MTT assay, an indicator for cell viability,
relies on changes in redox potential of the cells in
response to different agents. Following manufacturer
protocol, HepG2 cells were seeded (1x104 cells per
well) in 96-well plates. After being confluent, cells
were exposed to antituberculous drugs RIF (in
concentrations 1, 10, 100 μM and 1mM), INH and
PZA in concentrations (1, 10, 100 μM and 1 mM)
for a 4, 24 and 48 hrs in the presence of the drug or
DMSO. The MTT absorbance values were expressed
as a percent of the vehicle control (defined as 100%).
Each experiment was performed in triplicate with at
least 3 wells of each drug concentration in each
experiment.
Measurement of total glutathione
Reduced glutathione (GSH) was measured
according to Senft et al (2000). Cells were exposed
to IC50s of Anti-TB drugs and lower concentrations
(30 μM, 10mM and 3 mM of RIF, PZA and INH,
respectively) for 24 hr in 6 well-plates (106 cells per
well). Lower concentrations were tested individually
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or in combinations among the different Anti-TB
drugs. Then cells were scraped into ice-cold
phosphate buffered saline and centrifuged at 700 g
for 2 mins. The pellets were resuspended in ice-cold
lysis buffer and incubated on ice for 10 mins. After
that, they were centrifuged at 15000 g for 5 mins to
generate lysates and protein pellets. The GSH level
of the lysate was quantified using the fluorescent
substrate o-phthaladehyde (OPT) with an excitation/
emission wavelengths of 350/420 nm.
Reactive oxygen species (ROS) detection
3, 7-dichlorodihydrofluorescein diacetate
(DCFDA) assay was used to detect ROS. Cells were
cultured in 96-well plates (3x103/well) and treated
for 24 h with anti-TB at either its estimated IC50s
for viability or with lower concentrations (100 μM,
10mM and 3 mM of RIF, PZA and INH, respectively)
for 24 hr in 6 well-plates (106 cells per well). Lower
concentrations were tested individually or in
combinations among the different Anti-TB drugs
used individually or in combinations. The assay was
done following the protocol published in (Elmorsy
et al., 2014). DMSO was used as a vehicle control
and wells with non-stained cells were used as blank.
Each experiment was performed in triplicate, where
n represents the number of experiments (triplicates)
performed.
Effect of Reduced glutathione (GSH)
The MTT was done as shown in sections 2.4 in
the presence of reduced GSH (10 μM).
Statistical analysis
The statistical analyses were conducted using
PRISM 5 (GraphPad Software Inc., San Diego, CA).
For IC50 estimation, a non-linear curve fitting log
(inhibitors)- variable slope equation was used. For
comparisons, one-way ANOVA test with Dunnett’s
multiple comparisons post-test were used. Statistical
significance is defined as P<0.05. Significance is
indicated in the figures as *** for p<0.001, ** for
p<0.01 and * for p<0.05.
RESULTS
Anti-TB drugs decreased the viability of Hep-G2
cells
The MTT assay showed that the tested Anti-TB
drugs decreased the redox-potential of HepG2 cells
in a concentration and exposure times dependent
manners (Figure 1). RIF was the most cytotoxic with
the lowest IC50 (0.6 mM; 24hours post-exposure),
while PZA was the least cytotoxic with IC50 about
80 mM (24hours after exposure) (Table 1). PZA
showed a non-significant (P=0.189) cytotoxic effect
even with 1mM concentration in 4 hours post-
Fig. 1. MTT assay of the cytotoxicity of anti-TB drugs on
HepG2 cells.
HepG2 cells were treated with the anti-TB drugs RIF, INH,
& PZA in a wide range of concentrations for 4 hours, 24
hours and 48 hours.
treatment course, while RIF (100 and 1000 μM) and
INH (100 and 1000mM) significantly decreased the
viability of HepG2 cells within 4 hours after
exposure (P=0.005 and 0.002, respectively).
The effect of anti-TB on GSH
As shown in Figure 2, all the tested anti-TB
showed a significant reduction (P***<0.0001) of the
intracellular GSH content in comparison with the
controls in their IC50s. Total glutathione was reduced
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by about 40%, 45% and 35% with RIF, INH and PZA
respectively. Dunn’s post-test showed that only
RIF in the lower concentration (0.1 mM) showed
significant (P<0.05) reduction in HepG2 total
GSH (~20% blow the control levels). In 10 mM
concentrations, both INH and PZA showed no
significant decrease in HepG2 cells glutathione
stores by ~ 15% and 10% of the vehicle control cells
levels, respectively. In addition, INH in 3mM was
shown to increase significantly the effect of low
concentrations of RIF (0.1 mM) and PZA (10mM)
on HepG2 cells total GSH (P*=0.01and 0.042,
Table 1. Estimated IC50s (means and 95% confidence intervals) of the tested anti-TB
drugs in mM concentrations
RIF INH PZA
4 hrs Mean 12 132 124
95% confidence interval 0.3–48 34–596 91–186
24 hrs Mean 0.6 76 80
95% confidence interval 0.05–29 51–113 45–141
48 hrs Mean 0.02 70 77
95% confidence interval 0.007–0.88 37–130 34–178
Fig. 2. Effect of anti-TB drugs on the intracellular content of reduced glutathione in HepG2.
HepG2 cells were exposed to the anti-TB drugs (individually and in combinations) in different concentrations for 24 hours.
Then the intracellular contents of glutathione were assessed.
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respectively) with further more reduction of HepG2
cells glutathione by ~18% and 16% respectively in
comparison to the individual drugs treated cells.
Interestingly, combination of RIF (0.1 mM) and INH
(3 mM) significantly decreased HepG2 cells total
GSH in comparison with the vehicle control treated
cells (P*=0.023).
Anti-TB drugs increased Hep-G2 cells ROS
production
ROS experiments revealed that the tested anti-
TB increased significantly ROS production in
HepG2 cells (P***<0.0001) in comparison with the
vehicle controls in their MTT estimated IC50s
(P***<0.0001 for each anti-TB) (Figure 3). ROSs
production was increased to 138%, 144% and 136%
with RIF, INH and PZA respectively in comparison
to the vehicle control treated cells. In the lower
concentrations, [RIF (0.1mM), INH (10mM) and PZA
(10mM)], all the tested drugs did not show a
significant effect on HepG2 cells ROSs production.
In addition, pretreatment with INH (3mM) for 48
hours significantly increased the effect of RIF
(0.1mM) on HepG2 cells production of ROS (P
=0.0098). On the other hand, pretreatment with RIF
(30μM) for 48 hours significantly increased effect
of INH (10mM) on HepG2 cells production of ROS
(P =0.0066). Combination of RIF (0.1 mM) and
INH (3mM) significantly increased cellular ROS
production in comparison with control cells (P
=0.021*).
Reduced glutathione decreases the cytotoxic effect
of anti-TB drugs on Hep-G2 cells
Reduced GSH was shown to significantly
counteracted the cytotoxic effect of RIF and INH
(P=0.005 and 0.015, respectively) in their MTT
estimated IC50s while it showed no significant
(P=0.057) effect on the cytotoxic effect of PZA in
its IC50. Reduced glutathione increased the viability
Fig. 3. Effect of anti-TB drugs on HepG2 reactive oxygen species (ROSs) production.
HepG2 cells were treated with different concentrations of the anti-TB drugs (individually and in combinations) for 24 hours.
Then the intracellular content of ROSs production was studied.
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of anti-TB drugs treated cells by ~34%, 28%, 18%
of the control for RIF, INH and PZA, in their IC50s,
treated cells respectively. However, in the lower
concentration, reduced GSH showed no significant
effect with the all tested anti-TB drugs (Figure 4).
DISCUSSION
Tuberculosis induces oxidative stress as an
underline mechanism for their hepatotoxic effect.
HepG2 cells were used as a cell line model as they
are widely accepted model for liver studies. Anti-
TB drugs were assayed in a wide range of
Fig. 4. The protective effect of reduced glutathione (10mM)
on the anti-TB drugs induced cytotoxic effect on HepG2
cell.
HepG2 cells were exposed to RIF, INH, & PZA in absence
and present of reduced glutathione (10mM) forv 24 hours.
Then the cytotoxicity was studied by MTT assay.
concentrations covering their therapeutic, supra-
therapeutic, toxic and lethal levels (Winek et al.,
2001; Kayhan & Akgunes, 2011). Higher concentra-
tions were used to induce the desired cytotoxic
effect within the limited period of our experiments
to simulate the clinical state with prolonged clinical
therapeutic courses of the anti-TB drugs (for at least
6 months in the shortest protocols).
The present data revealed that the tested drugs
were cytotoxic to HepG2 cells. RIF was shown to
be the most potent. The tested anti-TB drugs, in
their estimated IC50s, were found to significantly
increased ROSs production and decreased
intracellular total glutathione. These results are in
agreement with the previous studies which showed
that anti-TB induce oxidative stress in rats and
human studies. In rats, the free radical scavenger
glutathione-related thiols, and antioxidant
glutathione peroxidase and catalase activities, are
diminished by isoniazid, although glutathione
reductase activity is increased (Sodhi et al., 1996;
Attri et al., 2001).
Regarding combinations in lower concentra-
tions, pretreatment with INH (3 mM) was shown to
increase the effect of both RIF (0.1mM) and PZA
(10mM) on the ROSs production and HepG2
intracellular glutathione content. In addition, RIF
(30 μM) pre-treatment for 48 hours was found to
significantly increase the effect of both INH (10mM)
on the both fore-mentioned parameters. This is
supporting the previous data showed that
combination of anti-TB drugs increased the risk of
hepatotoxicity. Taneja & Kaur (1990) reported that
the incidence of INH associated hepatitis was 6%,
this incidence was increased five folds when INH was
combined to RIF.
Regarding the combining of INH and RIF in
therapy, it is reported that the rate of symptomatic
hepatitis is 2.55% (Steele et al., 1991) while
combination of RIF and PZA has either less or
equal hepatotoxicity to isoniazid. The presence of
rifampicin in a multidrug treatment regimen
increased the incidence of significant hepato-
toxicity for adults from 1.6 to 2.55% and in children
from 1.0 to 6.9% (Steele et al., 1991). The influence
of pyrazinamide on TB DILI is ambiguous. Some
studies indicate little to no increased rate of
hepatotoxicity (Parthasarathy et al., 1986), whereas
others point to it as a contributor to increased
incidence or severity of hepatotoxicity (Teleman
et al., 2002; Yee et al., 2003), although dosing
variations and patient selection biases may have
contributed to these reported results.
In addition, the present study revealed that
introduction of exogenous glutathione diminished
RIF an INH induced cytotoxic effect in their
estimated IC50s. This in concordance with other
study in which antioxidant N-acetyl-cysteine, a
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substrate for glutathione synthesis, inhibits
isoniazid-induced liver injury in pretreated rats
(Attri et al., 2001). In addition, the active
components of silymarin was shown to have a
protective effect against hepatotoxic actions of the
first line anti-TB drugs used in the chemotherapy
of tuberculosis in male’s albino wistar rats model
(Eminzade et al., 2008).
The data of this study is clinically important
due to some concerns. Firstly, the present results are
highlighting the significance of oxidative stress in
anti-TB drugs induced hepatotoxicity. Secondly, the
study is appreciating the intake of exogenous
antioxidant as adjuvant therapy with the anti-TB
drugs to alleviate their hepatotoxic effects and
improve their tolerability. Thirdly, the data is
supporting more oxidative stress studies in the
newer anti-TB drugs development assays for better
outcomes and less incidence of hepatic injuries.
Fourthly, anti-TB drugs should be considered as risk
factors for severity of toxic agents, which are well
known to induce their toxic effect via oxidative
stress as antipsychotics and paracetamol toxicities.
In summary, we reported the significant
oxidative stress effects observed with Anti-TB drugs
on HepG2 cells. RIF is the most offending drug.
Oxidative stress plays a crucial role in their induced
cytotoxicities via production of excess amounts of
ROSs and depletion of glutathione stores. The
addition of exogenous antioxidant, GSH,
significantly decreased the cytotoxic effects of INH
and RIF, though this needs further expanded
clinical trials.
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